In August I posted a few questions related to Leica’s acquisition of Aperio. Among those dealt with to what degree would integration among their then separate existing portfolio of products would emerge among the other issues associated with an acquisition and at what rate would this happen. I posed the possibility of “Leica Biosystems ePathology Solutions Powered by Aperio” as what could become a recognizable brand of two leading companies in the life sciences space and digital pathology field. In effect, the combined portfolios of two leaders could take imaging from stainer to scanner to image analysis in a combined seamless solution. News today from Leica Biosystems announces interoperability with the combined Aperio ePathology portfolio comes about 7 1/2 months after the acquisition with the complete range of staining preparation to H&E, IHC, FISH, IF and reporting, providing an end-to-end solution for laboratories from stainer to scanner and beyond.
VISTA, CA – May 7, 2013 – Following the acquisition of Aperio, Leica Biosystems announced today two software releases facilitating interoperability throughout the combined Aperio ePathology portfolio.
“We are excited to complete this milestone in our portfolio integration, which is the first step in our ongoing commitment to provide world leading solutions and drive adoption of ePathology. These software releases mean that our customers can benefit from the synergy of our combined portfolio and enjoy the freedom to choose the ideal solution for their specific needs,” said Anne Brumme, Vice President of Research and Development, Pathology Imaging.
Digital Pathology users can now utilize images created on any of the ScanScope, Ariol or SCN400 Capture devices with a full range of Network software and Precision software solutions, for advanced sharing, collaboration and quantitative image analysis. Leica Biosystems now offers a full range of products for each step in the pathology process, from sample preparation and staining to imaging and reporting.
John Kody, Vice President and General Manager of Leica Biosystems, Pathology Imaging, further commented, “With the ever growing demands placed on pathologists worldwide and increased subspecialization, Aperio ePathology brings a new strength to the Leica portfolio, enabling us to help improve efficiency and rapid access to pathology expertise.”
Combined with the Leica Biosystems capability, the Aperio ePathology Solution suite now enables users to manage images from the complete range of ePathology capture platforms for H&E, IHC, FISH and immunofluorescence samples through a single interface, ensuring secure and rapid access to eSlides for remote, real-time viewing and distribution. This combined capability enables pathologists to have the right tools on a seamless pathology image management platform.
About Leica Biosystems
Leica Biosystems is a global leader in laboratory workflow solutions for anatomic pathology, striving to advance cancer diagnostics to improve patients’ lives. Leica Biosystems provides a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. Recognizing there is a shortage of pathology expertise worldwide, as well as increasing subspecialization, Leica Biosystems expanded its capability in pathology imaging with Aperio ePathology Solutions enabling greater access for pathologists through market leading whole slide scanners, Network solutions that enables remote, real-time viewing and easy distribution of images for collaboration and Precision solutions that provide pathologists with easy-to-use quantitative image analysis to improve clinical and research productivity, reproducibility and consistency. Leica Biosystems is represented in over 100 countries. It has manufacturing facilities in 6 countries, sales and service organizations in 19 countries, and an international network of dealers. Further information can be found at www.LeicaBiosystems.com.
Source: Leica Biosystems